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1. List of Abbreviations 
ADF                              Alive disease free  
ALL                   Acute lymphoblastic leukaemia 
AML                  Acute myeloid leukaemia  
ATG                   Anti-thymocyte globulin 
AWD                  Alive with disease  
BM              Bone marrow  
CMV                  Cytomegalovirus 
CNS                  Central nervous system 
CSF                    Cerebrospinal fluid  
CT                      Computed tomography 
DD                       Died of disease  
DIC                      Disseminated intravascular clotting 
DU              Death unrelated  
EBV                    Epstein Barr virus  
ESR                    Erythrocyte sedimentation rate 
FHLH                  Familial HLH 
Hb                       Haemoglobin 
HDL                     High density lipids  












HLH         Haemophagocytic lymphohistiocytosis   
IAHS         Infection related HLH 
IL             Interleukin 
IFN                        Interferon  
IVIG                     Intravenous immune globulin 
JRA                       Juvenile rheumatoid arthritis 
LB                        Liver biopsy  
LDH                     Lactate dehydrogenase 
LDL          Low density lipids    
LN     Lymph node  
LP             Lumbar puncture 
LPI            Lysinuric protein intolerance 
MAHS        Malignancy related HLH   
MAS         Macrophage activation syndrome  
NCC         No clear cause  
NKC         Natural killer cells 
NSAID       Non-steroidal anti-inflammatory drug 
Plts            Platelets  
RSV           Respiratory syncytial virus 












TBM          Tuberculous meningitis  
TG              Triglyceride 
TNF          Tumour necrosis factor 
VL            Viral load 
VLDL                    Very low density lipids   
WBC        White blood count  



































2. Letters of Intent 
 
          11 May 2010 
School of Child and Adolescent Health 
Dear Professor Zar 
Re: Research Proposal for Ethics Committee approval. 
Please find attached my submission for your approval, for a research project I wish to 
commence as part of my MMed during 2010. I plan to review the folders of patients admitted 
at Red Cross Children’s Hospital diagnosed with Haemophagocytic Lymphohistiocytosis. My 
supervisor for this study is Dr Marc Hendricks.  
Kind Regards 
Juli Switala 



























University of Cape Town 
Dear Colleague 
Herewith I attach my application for ethics approval for my study ‘Evaluation of Children with 
Haemophagocytic Lymphohistiocytosis (HLH) at Red Cross Children’s Hospital’. This is a 
descriptive retrospective study of patients who have been treated for this disease at Red Cross 
Children’s Hospital. I have received scientific approval from the School of Child and Adolescent 
Health and I would like to request an expedited approval as my study is a retrospective folder 
review, requiring no further recall of patients and no further investigations.  
This is a study that I am doing as part of my MMed and my supervisor is Dr Marc Hendricks at 

























1. Research Protocol 
 
Evaluation of Children with Haemophagocytic Lymphohistiocytosis (HLH) at Red Cross War 
Memorial Children’s Hospital 
Background 
Haemophagocytic Lymphohistiocytosis (HLH) is a rare haematological disorder in children. An 
estimated incidence of 0.12 per 100 000 children per year was found in a Swedish (Henter, 
Stockholm) study1. However, this is probably an underestimation due to the difficulty in 
diagnosing the disease.  
HLH is characterized clinically by persistent fevers, organomegaly, cytopaenias and typical 
biochemical derangements viz. hypertriglyceridaemia, hyperferritinaemia and 
hypofibrinogenaemia. Other associated findings include decreased natural killer cell (NKC) 
function and raised soluble CD 25.  
The exact pathophysiology of HLH is not completely understood but involves a trigger (often an 
infection) which sets off an uncontrolled inflammatory cascade, characterized by an increase in 
hyperactivated macrophages and T lymphocytes which leads to increased production of 
cytokines, alongside reduced cellular cytotoxicity as a result of reduced or absent NKC function. 
When functioning normally, NKCs play a role in lysis of cells by releasing cytotoxic proteins - 
perforins and granzymes, as well as by release of soluble mediators IFN-gamma, GM-CSF and 
TNF in response to pathogens. Once the foreign protein is destroyed, the stimulus for the 
immune activation is removed, and the reaction subsides. It follows therefore, that poor NKC 
function allows foreign proteins to persist and disseminate, causing increased, sustained 
activation of macrophages and a disproportionate increase in CD8 cells. This uncontrolled 
inflammatory response causes macrophage infiltration of tissue, as well as pro-inflammatory 
cytokine release, which likely accounts for the tissue damage and clinical picture associated 
with the disease2,3. TNF may be the cause of the hypofibrinogenaemia (it acts as a 












HLH is induced by strong, dysfunctional immunological activation. In primary HLH this arises as 
a result of a variety of mutations of the genes which encode for proteins involved different 
aspects of the granule dependant cytotoxic function of the NKC, such as perforin production3. 
Predominant mutations vary between different ethnic groups3. In secondary HLH this 
dysfunction may be related to infection, malignancy or auto-immune disease. 
HLH secondary to infection may be misdiagnosed as an ordinary infection4 due to the similar 
clinical syndrome1. Infection may also be linked to both onset and recurrences of primary HLH5. 
Epstein Barr Virus is a common trigger for both conditions5, and also carries the worst prognosis 
of the infection-associated HLH subtypes6. Other viruses (especially those in the herpes group), 
bacteria, protozoa, fungi and rickettsiae may also lead to the condition6. 
In addition, HLH may herald the onset of malignancies or auto-immune disease. It has been 
described in ALL, germ cell tumours, thymomas and carcinomas. It may present with a masked 
haematolymphoid malignancy such as lymphomas6.  
Auto-immune related HLH, more commonly known to rheumatologists as macrophage 
activation syndrome, can occur as a result of rheumatoid arthritis and SLE. 
The trigger in auto-immune related HLH may be viral infection or drugs, such as methotrexate 
or NSAIDs7.  
On reviewing 122 children on the international registry Arico et al found a 5 year survival of 
10% in children receiving chemotherapy alone and 66% for those who received an allogenic 
bone marrow transplant8 with a median survival time of 6 months in untreated children2. The 
disease is uniformly fatal in the absence of an HLA identical sibling bone marrow transplant, 
although chemotherapy alone may prolong survival1. Death may be due to neutropaenic sepsis, 
multi-organ failure or CNS manifestations4.   
The early diagnosis and initiation of appropriate treatment in HLH is crucial as it arrests the 
cytokinaemia and induces remission. In secondary phenomena, the diagnosis and control of 













Although the importance of timeous diagnosis of HLH has been highlighted, it may be a difficult 
diagnosis to make. The diagnosis is one of exclusion, and is typically made in a child with a 
documented, unremitting fever- often without a clear cause, with associated cytopaenias and 
organomegaly.  
Diagnostic criteria were established by the Histiocyte Society in 1991 and include fever, 
splenomegaly, cytopaenias involving at least two lineages, hypertriglyceridaemia and/or 
hypofibrinogenaemia and haemophagocytosis in bone marrow, spleen or lymph nodes. Five of 
these 8 features or a molecular diagnosis of HLH is needed to make the diagnosis5, 9. Criteria 
were adjusted in 2004 to include low NKC activity, hyperferritinaemia and raised serum 
concentrations of IL-2 r-α (CD 25). The alpha chain of IL-2 receptor increases during active 
disease making it good marker4. This occurs as a result of increased number of activated 
lymphocytes.  
This lymphocytosis also explains the hepatosplenomegaly (with transaminitis and 
hyperbilirubinaemia) and the many manifestations of CNS disease4. Although serum CD 25 may 
differentiate HLH from other conditions, the time delay, and lack of availability at many centres 
limit its usefulness9. Raised serum ferritin and decreased serum fibrinogen occur as a result of 
activated macrophages which secrete ferritin and promote high levels of fibrinolysis4. 
Allen et al have shown a ferritin level >10 000 mcg/l to be 90% sensitive and 96% specific for 
HLH9. Hyperferritinaemia is not unique to HLH and other differentials must be considered. 
Lysinuric protein intolerance (LPI), is an autosomal recessive disease in which high ferritin levels 
are present10. Congenital haemochromatosis also causes hyperferritinaemia and may mimic 
neonatal HLH, as both can present with deranged liver functions, similar clinical phenotypes 
and hepatomegaly10. Hereditary Hyperferritinaemia-Cataract Syndrome is another rare cause of 
hyperferritinaemia10. 
Raised serum triglycerides are found early in the disease, and resolves with remission. LDL and 












Because of the potential morbidity and mortality encountered in this disease, early diagnosis is 
paramount. We will review the epidemiological data of these patients including their 
biochemical markers in an attempt to gauge their usefulness as early indicators of HLH.  
 
Objectives 
1. To evaluate the epidemiological features of children with HLH. 
2. To evaluate different biochemical markers of disease and to assess their usefulness as    
predictors of disease. 
3. To assess whether threshold values for ferritin and triglycerides are helpful in identifying 
those who are most at risk / likely of having HLH. 





A retrospective folder review.  
2.Sample 
15 patients treated at Red Cross War Memorial Children’s Hospital  
Inclusion criteria:  
Any child with confirmed HLH as assessed by 2004 HLH diagnostic criteria 4. 














 Patient notes will be reviewed and a database will be created.  
4. Analysis 
Data will be descriptively reported with specific reference to the questions set out in the 
objectives. 
5. Dissemination Plan  
The study results will be prepared for submission for an MMed thesis. Findings of the study will 
be presented at Research Day as a vehicle to educate local staff about early diagnosis and 
treatment. We will submit our findings for publication to the Journal of Paediatric 
Haemataology and Oncology or an equivalent. 
6. Costs 
There will be no costs involved in this study. 
7. Conflict of Interests 
The authors wish to declare no conflict of interest. 
8. Ethical Considerations 
As this is a retrospective folder review, patient management will not be affected in any way. 
Complete confidentiality will be ensured as patients will have numeric identifiers. No further 
recall of patient will be necessary and no further investigations will be undertaken. Patients will 
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3. Literature review 
 
Evaluation of Children with Haemophagocytic Lymphohistiocytosis (HLH) at Red Cross 
Children’s Hospital. 
Background 
Haemophagocytic Lymphohistiocytosis (HLH) is a rare haematological disorder in children. An 
estimated incidence of 0.12 cases per 100 000 children per year was reported in a Swedish 
study1. However, this is probably an underestimation due to the difficulty in diagnosing the 
disease. 
HLH is characterised clinically by persistent fevers, organomegaly, cytopaenias and typical 
biochemical derangements - primarily hypertriglyceridaemia, hyperferritinaemia and 
hypofibrinogenaemia. In 1952 Farquhar and Claireaux described what is now known to be 
familial HLH2 and in 1979 Risdall described similar findings in immunosupressed patients3.  
These patients often had proven herpes or adenovirus infection and all had bone marrow and 
lymph node infiltration, lymphocyte depletion, hepatocellular necrosis and leptomeningeal 
involvement4.  
Pathophysiology  
The exact pathophysiology of HLH is not completely understood. It is thought to arise as a result 
of a hyperactivated, yet inefficient immune system. When functioning normally, NKCs play a 
role in lysis of cells by releasing cytotoxic proteins - perforins and granzymes, as well as by 
release of soluble mediators IFN-gamma, GM-CSF and TNF-alpha, IL1, 6, and 10 and 
macrophage colony stimulating factor in response to pathogens5. Once the foreign protein is 
destroyed, the stimulus for the immune activation is removed. In HLH, foreign cells stimulate T-
cell activation and proliferation, but then fail to remove the stimulus due to poor NKC function, 
allowing foreign material to persist and disseminate, activating more T-cells and macrophages, 












CD8 cells.  This uncontrolled inflammatory cascade and organ infiltration likely accounts for the 
tissue damage and clinical picture associated with the disease6,7 . 
The trigger for this cascade is typically a viral infection, but may be any infection, a toxin, a 
metabolic product, profound stress or tissue damage8. Chemotherapy and immune suppression 
post transplantation may also activate the immune system8, although the exact mechanism is 
not well delineated. 
 
Classification 
HLH is not a single disease but a clinical syndrome, induced by strong, dysfunctional 
immunological activation. Primary and secondary forms of the disease are histologically 
indistinguishable. 
A: Primary HLH  
The immune defect may be genetic (primary HLH), in which the actual mechanism of NKC 
dysfunction, viz. poor perforin or granzyme production, or poor exocytosis of granules, is a 
function of the gene mutation.  HLH is induced by strong, dysfunctional immunological 
activation. In primary HLH this arises as a result of a variety of possible mutations of the genes 
which encode for proteins involved in different aspects of the granule dependant cytotoxic 
function of the NKC, affecting processes such as perforin or granzyme production, or exocytosis 
of granules 7. Predominant mutations vary between different ethnic groups7.   
The inheritance may be autosomal recessive, with a reported frequency of one per 50 000 
births5,9. Seventy percent of patients develop symptoms in the first year of life1,5. In utero 
development of primary HLH has been described and the upper age limit is not known1.  
Different gene mutations result in different pathophysiological mechanisms of disease by 
affecting either the NKC or perforin production. The exact gene mutations differ in patients 
with different ethnicities6,10. The perforin gene PRF1 mutations are currently thought to be the 












between 20-30%8. Other implicated genes include 10q21–22, UNC13D and STX1110,11. In a study 
by Lee et al, British and American patients of African descent were all shown to have the same 
gene mutation on the perforin gene PRF1 (50delT) which occurred exclusively in this ethnic 
group12. Similarly, Celtica et al found that 90% of patients of African descent had this founder 
mutation10. Phenotypically, it is associated with an earlier age of onset compared to other PRF1 
mutations. By comparison, the most common mutation amongst Turkish patients (p.W374X) is 
not exclusive to this group, possibly as a result of gene migration10.  
Two subgroups of primary HLH are described:  
1) Familial HLH (FHLH), a group in which HLH is the only manifestation.  
2) A second group, in which HLH is a sporadic but frequent association, but not the only feature of 
disease. This is found in children with primary immune deficiencies like X-linked 
lymphoproliferative disease, Chediak Higashi syndrome or Griscelli syndrome5, 13. 
   
B: Secondary HLH 
Secondary HLH is induced by an immunological stressor, typically an infection, but malignancy 
and auto-immune disease may also precipitate the syndrome. A trigger is not always identified, 
making differentiation between primary and secondary HLH difficult. There is no way to reliably 
differentiate primary from secondary disease clinically, although secondary HLH tends to 
present after one year of age8. 
1) Infection related HLH (IAHS) 
Secondary HLH is typically related to infection. The relationship between infection and HLH is a 
complex one. Due to the similarity of the clinical features, HLH may be misdiagnosed as an 
infection initially. When both occur concurrently the infection may be the trigger of IAHS or 
primary HLH1, 4, 11, 13, or be a result of the decreased immunity associated with HLH. 
Epstein Barr Virus (EBV) is a common trigger for both primary and secondary HLH11 and carries 












associated cases5. It has a higher prevalence in Asia than in western countries and this may be 
due to genetic or environmental factors8. The spectrum of infectious precipitants of HLH is 
substantial. Viruses, especially those in the herpes group, bacteria, protozoa, fungi and 
rickettsiae have all been implicated4,10. HIV, M.Tuberculosis and Plasmodium spp. have also 
been reported14 - all important diseases in sub-Saharan Africa. IAHS has a reported mortality 
rate of more than 50% in children by Janka et al8. 
2) Malignancy associated HLH (MAHS) 
The incidence of MAHS is not known. Two patterns have been described4.  
1) The first is characterised by HLH which develops as a result of an infection or unknown 
trigger, long before or during treatment for malignancy. The malignancy itself may respond to 
treatment and HLH may only become evident months later. Malignancies reported to display 
this pattern of presentation include acute lymphoblastic leukaemia, multiple myeloma, germ 
cell tumours, thymomas and certain carcinomas. 
2) The second is characterised by HLH which develops rapidly in an apparently healthy child or 
adult, in which the malignancy is initially masked but later diagnosed. This has been reported 
preceding T- cell leukaemia, anaplastic large cell lymphoma, and adult B-cell lymphoma. 
   
3)  Auto-immune related HLH  
Also known as macrophage activation syndrome (MAS), it was first described in 1985 in patients 
with rheumatoid arthritis and SLE8. Up to 7% of patients with systemic juvenile rheumatoid 
arthritis may develop MAS with a reported mortality rate of 10 -20% 13. Triggers include viral 


















HLH may be extraordinarily difficult to diagnose. The importance of early detection cannot be 
overstated, as the commencement of medical therapy is critical to survival. The diagnosis is one 
of exclusion and is typically made in a child with a documented, unremitting fever, often 
without a clear cause, with associated cytopaenias and organomegaly. A high index of suspicion 
is required, in a clinical setting where the differential diagnosis may be broad and the clinical 
course may vary considerably. Atypical presentations may further complicate matters. For 
example, neonatal onset disease may have a less prominent fever, which is usually a cardinal 
feature1. In addition, some patients experience improvements in their symptoms following non-
specific therapies like blood transfusions or antibiotics8. The average time to diagnosis varies 
between studies from seven days to four weeks15, 16.  
In 1991 the Histiocyte Society proposed a set of diagnostic criteria which included documented 
fever, splenomegaly, and cytopaenias involving at least 2 lineages, hypertriglyceridaemia 
and/or hypofibrinogenaemia and haemophagocytosis in bone marrow, spleen or lymph nodes. 
The criteria were amended in 2004 to include low NK activity, hyperferritinaemia and raised 
levels of serum IL-2 receptors (CD25). Five of these eight features or a molecular diagnosis of 
HLH is needed to make the diagnosis (Table I)11. Since then a slight modification has been 
proposed, but not yet codified (Table II). These modifications incorporate more clinical features, 
are less stringent and allow for the diagnosis of ‘suspected HLH’.  
Clinical criteria and features 
70-80% of patients with FHLH are symptomatic within the first 12 months of life13. Secondary 
HLH typically presents later in life, but both diseases ultimately run a rapidly fatal course16, 
unless treatment is instituted.  Each clinical feature and biochemical abnormality is as a result 













Fever and Tissue Involvement 
Fever is caused by the release of IL-1 and IL-6, and is typically protracted13. Henter et al 
compared the frequency of initial clinical features in patients on the FHL registry with those in a 
population based study, as well as those found in a literature review. In all three populations 
fever and splenomegaly were present in more than 90% of patients. Similarly, hepatomegaly 
was present in 94% of the patients in the literature review and 97% of the study patients, but 
insufficient data was available for the registry population. Hepatosplenomegaly is reported to 
be marked and progressive and is accompanied by transaminitis and hyperbilirubinaemia1.  
Lymphadenopathy and skin rash were less consistent findings, varying from 17-51% and 6-65% 
respectively between the groups1. The rash is usually transient and associated with fever1. 
Pulmonary symptoms may also develop as a result of infiltration by activated lymphocytes. 
            Neurological disease 
Neurological features associated with HLH include seizures, hyper- or hypotonia, a bulging 
fontanel, irritability, neck stiffness, ataxia, blindness, encephalopathy, psychological depression,  
opisthotonus, hemi- or tetraplegia, a depressed level of consciousness and 6th and 7th cranial 
nerve palsies1, 13, 16.These may be present early in the disease or may evolve later1, 16. Haddad et 
al found that 25 of 34 patients had CNS involvement at presentation. Twenty of these 25 had 
CSF abnormalities with no clinical features apart from neck stiffness17. In this study, 
development of CNS symptoms was associated with an inferior outcome. Seizures were found 
to be the commonest manifestation in young patients. In a series by Hallahan et al 75% of 
patients developed CNS involvement at some point during the course of disease, but most did 
not present with features initially. Again, CNS involvement worsened prognosis in this group16. 
Biochemical markers and investigations 
Typical serum biochemical findings include hypertriglyceridaemia, hypofibrinogenaemia or 
coagulopathy, elevated LDH, liver dysfunction and marked transaminitis, hyperferritinaemia, 
raised VLDL and decreased HDL and raised cytokines in both serum and CSF9. These changes 













Ferritin is an iron binding protein consisting of light and heavy chains. Oxidative stress and pro- 
inflammatory cytokines from the NKC pathway up-regulate transcription of the ferritin heavy 
chains. Ferritin can therefore be used as an indirect measure of cytokine activation15.  
As a ferritin level may be acquired much faster than a functional NKC assay or IL-2 α receptor in 
most centres, it is of more practical significance in the acute setting15. 
            Hyperferritinaemia is not unique to HLH and other differentials must be considered. Lysinuric 
protein intolerance (LPI) is an autosomal recessive disease in which high ferritin levels have 
been reported. This is now understood to be due to a form of HLH related to LPI18. Congenital 
haemochromatosis also causes hyperferritinaemia and can mimic neonatal HLH, since both can 
present with deranged liver function, a similar clinical syndrome and hepatomegaly18. 
Hereditary hyperferritinaemia-cataract syndrome is another rare cause of hyperferritinaemia18. 
Ferritin may be elevated in infections but values are not likely to exceed 200mcg/l8. In a study 
by Allen et al, a ferritin level >10 000 mcg/l was found to be 90% sensitive and 96% specific for 
HLH (98% if fever was added as a criterion)15. By comparison serum ferritin levels in JRA without 
MAS may exceed 10000mcg/l8. In a series of patients including both viral- and malignancy 
associated HLH, Esumi et al found ferritin levels to be elevated at diagnosis, with further 
increases at the onset of DIC. Patients with sustained high ferritin levels after three months 
died, while those with decreased levels survived, suggesting that ferritin level may be a useful 
marker of disease activity and not just the presence of disease19.    
CD 25 (IL 2α receptors) 
By comparison the alpha chain of the IL-2 receptor is made by activated histiocytes and T-cells. 
It increases during active disease and is cell specific. Janka et al8 found it to be the most 
sensitive marker (93%) for HLH. Specificity is also high8,15 making it a good marker to 
differentiate HLH from infection. Diagnosis may be complicated by the fact that elevated levels 
may also be found in leukaemias and lymphomas8. The lack of availability to perform this test at 













Hypofibrinogenaemia may not be present on initial testing but may develop later. Depressed 
serum fibrinogen levels occur as a result of the increased numbers of activated macrophages 
secreting plasminogen activating factor, which promotes high levels of fibrinolysis13. Risdall et 
al reported clotting abnormalities in 68% of patients with viral-associated HLH3. These consisted 
of prolonged partial thromboplastin and thrombin times and normal to prolonged prothrombin 
times3. 
Hypofibrinogenaemia may be useful in differentiating HLH from infection, as in most infections 
(other than DIC), fibrinogen is typically normal or raised8. Janka et al reported a sensitivity of 
only 53%8.  
The Bone Marrow 
Pancytopaenia is ascribed to the effects of TNF- α and interferon-gamma on bone marrow 
precursor cells13. The platelet count typically increases during remission and may decrease at 
relapse. These changes occur relatively early on, making the platelet count a useful monitor for 
active disease1. The reticulocyte count may be inappropriately low for the severity of the 
anaemia, due to the increased, but ineffective erythropoesis in the bone marrow8, not unlike 
other bone marrow failure syndromes, like aplastic anaemia or leukaemia. 
Bone marrow aspiration may provide histological evidence of HLH and help to exclude   
malignancies. The classic features are histiocyte hyperplasia and widespread infiltration of 
normal haemophagocytic macrophages and lymphocytes3,6,8. The bone marrow appearance 
varies considerably depending on when in the course of the disease it is performed6.  
The haemophagocytosis may be absent initially, and repeated aspirations may be required to 
demonstrate it. When it develops, histiocytes are most commonly seen engulfing erythrocytes 
but may also phagocytose lymphocytes and platelets8. Cellularity may wane in later stages or 
after therapy, giving the bone marrow an aplastic appearance1. Histiocyte hyperplasia and 
haemophagocytosis may persist for up to 5 months after recovery in some patients, but in 













Hypertriglyceridaemia is usually found early in the disease, and resolves as the disease remits1. 
This occurs as a result of the inhibition of lipoprotein lipase by TNF-α13. LDL and VLDL levels are 
usually markedly increased, and HDL decreased1.  
Elevated LDH 
Imashuku et al found a higher incidence of raised LDH than hypofibrinogenaemia and 
hypertriglyceridaemia, suggesting that it may be a useful marker for active disease20. 
Natural Killer Cells 
NKC dysfunction is a cardinal feature of HLH. In FHLH the number of NKCs may be normal, but 
defective. This defect persists even between episodes of active disease. In secondary HLH, both 
the number and function of NKCs are deficient during active disease with function typically, but 
not always, normalising between episodes8, 13. 
Cerebrospinal Fluid and Neuro-Imaging Abnormalities 
Cerebrospinal fluid (CSF) may have raised protein, lymphocytes and occasional erythrocytes5. 
CSF changes may be present even without any clinical features8 or conversely CSF may appear 
normal, even in patients with symptomatic CNS involvement16. For this reason, Janka et al 
recommend a lumbar puncture be done in all patients8 as CNS involvement is associated with a 
worse outcome16. CSF neopterin levels may be a useful marker of disease as it indicates 
histiocyte activity16. Neuroimaging may show some features of ongoing or previous 
inflammation or demyelination. Findings include haemorrhage, infarction, atrophy and     
oedema1,16. 
Tissue Biopsy 
When indicated and where possible, histological examination of tissue such as nodes, liver, and 














Initial management is aimed at arresting the life threatening hyperinflammatory process. Once 
control of the cytokine response has been achieved, the stimulus for its continuous activation 
needs to be removed. Finally, as in FHLH, the dysfunctional immune system needs to be 
permanently replaced8. Treatment modalities therefore include chemotherapy, 
immunotherapy, bone marrow transplant and the treatment of triggers and complications. 
Corticosteroids arrest the cytokine cascade by destroying lymphocytes, inhibiting dendritic cell 
differentiation and reducing chemokine and cytokine expression8. Dexamethasone is preferred 
to prednisolone as it has superior blood brain barrier penetration11, 13. 
Etoposide is an epipodophyllotoxin derivative. It was first used for treatment of HLH in 19808. It 
reduces the activation of the cytotoxic cells by destroying the antigen presenting cells13. It also 
inhibits synthesis of EBV nuclear antigen, and may prevent clonal expansion of virus-infected 
cells8. Ambruso reported prolonged remission with its introduction, in combination with 
steroids in 198021. Etoposide is myelotoxic which may pose a problem in a disease in which 
cytopaenia and immunodeficiency are prominent11. There is also a concern about the risk of 
developing a secondary leukaemia with the use of etoposide, as acute myeloid leukaemia and 
myelodysplastic syndrome have been reported in associated with epipodophyllotoxin 
derivatives1,9. This risk is considered to be of less significance than the risk of under treatment 
for HLH1. The risk of developing secondary AML, which is dose related, may be reduced by 
combining its use with immunotherapy (cyclosporin)9. Most modern protocols keep the 
cumulative etoposide dose well below the threshold which would put one at risk for a 
secondary leukaemia.  
Cyclosporin has been used effectively to induce remission in HLH by affecting T-lymphocyte 
action and macrophage function. It interferes with the cyclophilin pathway thus causing 
immunosuppression8. It has been used successfully as a single agent for maintenance in HLH, 
rheumatic disease and MAS10. Another immune modulatory agent, antithymocyte globulin 
(ATG) has been shown to induce remission and may in future be used in resistant cases as part 












Immunoglobulins act by cytokine and pathogen-specific antibodies which stimulate Fc receptor 
function8. Intravenous recombinant immune globulin (IVIG) has been shown to be of use in 
children with IAHS, in some cases inducing a response even when administered alone4.   
Ladisch et al found that the plasma of three patients with HLH had a lymphoproliferative 
inhibitor effect on normal, control mononuclear cells22. Although the reason for this is not 
entirely understood, this finding implies that removal of a plasma factor by exchange 
transfusions potentially reduces this inhibition. However, transfusions during relapses showed 
less response. These findings may be due to the ability of red cells to absorb cytokines8, 22. 
Bone marrow transplantation is the only way to restore a normal immune system, and it can be 
curative in up to 2/3 of patients8. Best results are achieved with HLA-matched siblings11. If this 
is not possible a matched unrelated donor is advised11.  
Current Treatment Recommendations 
The Histiocyte Society developed a study group with diagnostic guidelines in 1991 and the first 
treatment recommendations in 1994. This was known as the HLH-94 protocol. With the 
collective experience gained from this protocol, HLH-2004 was developed which included 
revisions to the diagnostic criteria as well as treatment guidelines11. Appropriate treatment 
differs depending on the type of HLH, identification of a trigger and the severity of symptoms. If 
an infective agent is identified, anti-infective therapy may be the only treatment needed in a 
mild form, although this is usually not the case8.  
In mild to moderate secondary HLH, corticosteroids and immunoglobulins may be sufficient8, 13. 
However, mild cases may progress rapidly and even  in patients with proven EBV-related HLH, 
etoposide based regimens have a better outcome than those on corticosteroids,  cyclosporin A,  
immunoglobulins or a combination of these8. Finding an infectious cause in children older than 
1 year is not sufficient to exclude primary HLH. Janka et al advise treating all critically ill children 
and those less than 1 year according to HLH protocol as the risk of under treating a patient with 












recommends starting all patients, regardless of evidence of genetic disease, and viral infections 
on multi-agent intensive therapy11. 
HLH-94 recommended using a combination of steroids and etoposide, and in some patients, 
intrathecal methotrexate, as initial therapy for 8 weeks. Continuation therapy included 
dexamethasone pulsed therapy, etoposide and the introduction of cyclosporin A. This aimed to 
stabilise patients awaiting bone marrow transplant9.  
In HLH-2004, initial therapy is intensified by including cyclosporin A from the outset11. This 
modification was made as some patients had died from the disease itself during the first 8 
weeks of treatment11. In patients who achieve resolution after the initial phase and have no 
family history, treatment is stopped11.   
In patients with verified primary HLH or severe, persistent or reactivated secondary HLH, 
continuation therapy should be continued while awaiting a bone marrow transplant11. 
Reactivation is part of the clinical picture of primary HLH, and these are most likely as the 
intensity of therapy is reduced or a new immune response trigger occurs (e.g. viral infections, 
vaccinations). Intensification of therapy is recommended in these patients11. 
In patients with CNS involvement, adequate systemic therapy has been shown to decrease 
active CNS disease11 and intrathecal therapy alone has not been particularly effective9. It is not 
known whether or not intrathecal therapy in addition to initial systemic therapy would be of 
added benefit11. As such, both HLH-94 and HLH-2004 recommend  intrathecal  methotrexate  
be reserved for patients with evidence of  persistence or  progression of CNS disease after 2 
weeks of treatment or CNS reactivation1,9,11. HLH-2004 advises corticosteroids be added to 
intrathecal therapy11. As some patients develop asymptomatic CNS involvement8. As a 
minimum, CSF analysis is recommended at the time of onset, and during reactivation of 
systemic or neurological features11. 
For patients with rheumatic disease and associated HLH, cyclosporin is recommended either as 
first line therapy or as a second line agent, if high dose corticosteroids do not achieve an 












In MAHS, treatment depends on the clinical scenario. It is focused on treating the malignancy 
and possible infections in patients not yet on chemotherapy. If a child is on chemotherapy and 
the malignancy is controlled appropriate treatment might include an interruption of 
chemotherapy, along with treatment of infection, steroids and etoposide. In rapidly progressive 
MAHS initial therapy is aimed at controlling the acute cytokine storm with steroids and 
etoposide focusing on the treatment of the malignancy once the patient is more stable4. 
Supportive therapy recommendations (HLH-2004) during the initial phase include, broad 
spectrum antibiotics when required, prophylactic oral co-trimoxazole, an oral antifungal, and 
possibly an oral antiviral agent. Immunoglobulins once every 4 weeks, and gastroprotective 
therapy (e.g. with Ranitidine) is also recommended11. A retrospective review of adverse 
outcomes of patients treated at the Hospital for Sick Children by Sung et al found that 50% of 
deaths were due to invasive fungal infection, emphasizing the need for a low threshold in 
starting antifungal treatment during prolonged neutropaenia, as well as prophylactic antifungal 
during chemotherapy23. 
In patients with FHLH, genetic counseling and prenatal diagnosis in future pregnancies should 
be offered to the parents. 
Prognosis 
The mortality in primary HLH is high. The disease is uniformly fatal in the absence of an HLA 
identical sibling bone marrow transplant, although chemotherapy alone may prolong survival1. 
On reviewing 122 children on the international registry Arico et al found a 5 year survival of 
10% in children receiving chemotherapy alone and 66% for those who received an allogeneic 
bone marrow transplant24.Death may occur as a result of neutropaenic sepsis, multi-organ 
failure or CNS disease13. The median survival time without treatment is 2-6 months1,6,9.  
In secondary phenomena the diagnosis and control of precipitating disease entities is crucial in 
arresting evolving clinical disease and preventing death. In a review of  paediatric cases of IAHS 
reported between 1979-1996 (n= 219) by Janka et al4,  the reported mortality rate was 38% in 












one year(68%). Amongst the infective precipitants, bacteria-related HLH had the best prognosis 
(82% survival), and EBV related, the worst (22% survival).  
Using the treatment guidelines in HLH-94, 119 patients were followed up by Henter et al 
between 1994-1998. The 3 year overall survival was 55% for HLH and 51% for patients with 
FHLH. Patients who survived without a bone marrow transplant were all retrospectively 
presumed to have had non-genetic forms of the disease. No familial cases survived without 
transplant. A 64% 3 year overall survival was found in patients after haemopoeitic cell 


























4. Database Review 
Methods  
A retrospective review of data was performed using hospital folders of all children who met the 
diagnostic criteria for HLH (Table I) treated at Red Cross War Memorial Children’s Hospital 
between March 1991 and September 2010. Cases were identified using the institutional Red 
Cross Oncology Registry.     
All patients with Langerhans Cell Histiocytosis, malignant histiocytoses or those who did not 
meet the diagnostic criteria for HLH were excluded. 
Prior to 1991 four patients who presented with histopathological features of a 
haemophagocytic syndrome were excluded, as there was no other record of serological 
identifiers for disease apart from cytopaenias. 
 
Results 
Fifteen patients met the criteria for the diagnosis of HLH. Eight of the patients were female, 
seven male. The median age at diagnosis was 27 months (10-79 months) for males and 75 
months (9-225 months) for females. Henter et al reports a male: female ratio of 1:1 1.  
We did not classify any of our patients as having fHLH. There were multiple reasons we felt that 
secondary HLH was more likely:   
 None of the patients included in the study had a documented family history of HLH, and no 
folders contained any history of consanguity or unexplained family illnesses or deaths related to 
haematological problems (This does not exclude familial HLH, as it is an autosomal recessive 
trait1).  
 The age of the patients: Of the three patients were under 1 year of age at diagnosis, the age at 
which primary HLH is likely to present1, two are alive disease free and one died of an unrelated 












diagnosis, an age they would have been unlikely to reach in the presence of  severe immune 
deficiency.  
  In most patients we had a reasonable degree of certainty that we had established a primary 
cause.  
 In all patients with refractory disease, remission was eventually achieved by increasing the 
doses of steroids and/or adding a second or third agent and lengthening the eight week 
induction. 
Ten patients are black, four of mixed ancestry and one patient is Bangladeshi. There are no 
Caucasians in our cohort. According to Henter et al HLH has been reported in many ethnic 
groups, from all continents1. 
The median time to achieve a diagnosis once the children had arrived at our own institution 
was 13.7 days (1- 38 days) compared to seven days to four weeks reported in the literature15, 16.  
In certain cases the time to diagnosis was shortened due to referring units pre-emptively 
discussing the case with the Haematology/Oncology department. This undoubtedly shortened 
the interval to diagnosis, and the commencement of treatment. 
Clinical features (see Table V) 
Fever was documented in 13 (87%) patients. This is in keeping with previous studies with larger 
cohorts of patients (91-100%) as reviewed by Henter et al1. The actual duration of fever was 
only available for seven patients, and this included fever noted by parents and referral centres. 
The median duration of fever in these patients was 19.2.days (1-51 days). One patient was 
referred with a history of intermittent fever for 6 months.  
Splenomegaly was documented in 10 (67%) patients compared to 97-100%1. Despite 
hepatomegaly not being a diagnostic criterion, it was present in 11(73%) patients compared to 
94-97% in an earlier study1.  Other common features were rash (7 [47%, compared to 6-65%1]) 












Five patients were found to have clinical CNS involvement which is lower than the 75% found in 
a series by Hallahan et al, although in most of these patients CNS features were not present 
initially but developed later in the clinical course16. Signs included non-specific pain, refusal to 
weight bear, abnormal gait, hydrocephalus, meningism, strabismus, hypotonia, weakness and 
neuroregression. One patient had no clinical CNS disease but had an abnormal CSF and 
meningeal enhancement on CT scan. In our setting meningeal enhancement is more commonly 
associated with meningitis, particularly tuberculous meningitis (TBM), but the CSF findings did 
not support a diagnosis of TBM. 
Precipitants 
All of the patients included in the group were classified as having secondary HLH. Ten patients 
had clear precipitants. In three patients EBV was the precipitating cause (viral load log values   
of >4). One of these three patients also had SLE. Eleven patients had evidence of previous EBV 
(IgG positive or viral loads log values of 3.2 - 4). One patient had no evidence of EBV. 
Other precipitants included CMV and RSV (1) in the same patient, pneumococcal endocarditis 
(1), Kawasaki disease (1), acute lymphoblastic leukaemia (on maintenance chemotherapy) (1), 
acute myeloid leukaemia (preceding diagnosis of malignancy) (1), anaplastic large cell 
lymphoma (preceding the diagnosis of malignancy) (1) and T- cell lymphoma (on maintenance 
chemotherapy) (1). No clear precipitant was found in the five remaining patients. 
Investigations 
 14 patients had documented serum ferritin levels at diagnosis. Thirteen had levels above 
500mcg/L. The highest ferritin level was recorded was 10 000 mcg/L. This  is useful as Allen et al 
found a ferritin level on admission of above 500mcg/L to be 100% sensitive for HLH15. 
All patients had multiple full blood counts .The first values demonstrating an abnormality were 
recorded, and in many cases results continued to deteriorate before normalizing. HLH is a 
progressive disease and as such biochemical changes are dynamic. All 15 patients had 












al reported anaemia in 89-94% of patients1. Despite it’s sensitivity, low serum haemoglobin has 
a broad differential , so anaemia in isolation is not a particularly meaningful finding. 
The median white cell count was 17.2 x 109/L (1 - 63.1 x 109/L) and five patients had values 
under 4x109/L. The median platelet count was 68 x 109/L (13 - 145 x 109/L). 
Seven of 14 patients (50%) who had serum triglyceride levels tested had elevations in excess of 
3mmol/L. None of the records reflected whether or not children were fasted prior to 
triglyceride levels being tested. Henter et al reported hypotriglyceridemia in 80-100% of 
patients1. 
Six of the 13 patients who had recorded serum fibrinogen levels were below 1.5g/L. Sensitivity 
is reported as 53-64% in the literature3,8, but this test is useful as fibrinogen is usually increased 
in infection- often the primary differential diagnosis. 
An elevated serum LDH of more than 1000 U/L is considered supportive evidence for HLH16. 
Only 3 of 15 patients in the cohort had elevated serum LDH levels. 
Nine patients had lumbar punctures performed. Histiocytes were seen in the CSF of 3 patients, 
but no patients had an elevated CSF protein. CSF neuroleptin levels are not available at our 
institution.  
All patients had bone marrow biopsies at diagnosis. All bar one demonstrated 
haemophagocytosis with histiocytic infiltration. One patient was thought to have an immune 
thrombocytopenia based on a bone marrow done at five months of age, which showed an 
anaemia of chronic disorders and increased megakaryocytes with peripheral blood 
thrombocytopenia. She was admitted a second time at 14 months of age with sepsis. A second 
bone marrow then revealed HLH.  
One patient had haemophagocytosis present on a lymph node, bone marrow and skin biopsy. 
She presented with superior vena caval syndrome and airway obstruction, which required 
intubation and ventilation. Subsequently a diagnosis of anaplastic large cell lymphoma was 












Blood Product Support  
Twelve patients required transfusions of packed cells. The median number of transfusions per 
patient was 9 (1-34 transfusions). Nine patients received platelet transfusions (1-18). Two 
patients received cryoprecipitate and three patients fresh frozen plasma. 
Treatment 
Thirteen of the fifteen patients received steroid therapy. Two patients demised, one before any 
treatment could be commenced, and a second from an unknown cause at her referral hospital 
six months after discharge. 
Of the thirteen, ten patients were started on dexamethasone, nine at 10 mg/m2 and one 
patient (who was on maintenance therapy for T-cell lymphoma at the time) was started on 
5mg/m2. Two patients were treated with prednisone. One patient was started on prednisone 
initially but was changed to dexamethasone (10mg/m2) nine days later. 
Six patients were started on etoposide and two on cyclosporine (as per the HLH 2004 protocol) 
together with steroid therapy. 
No patients came to bone marrow transplant.  
Outcomes  
Ten patients are alive: six are disease free, one has refractory disease still on treatment, one 
with relapsed disease and two still on the induction phase of treatment. Four patients have 
died; one from refractory HLH, one from relapsed HLH, one from end stage HIV and one from 
an unknown cause. One patient was lost to follow up. 
Of the three patients with relapsed disease, two have died of disease. The third patient 
relapsed after being treated with steroid alone and is currently on second line therapy with 














The first patient with presumed HLH was diagnosed at Red Cross in 1973. 
This patient, who has been excluded from the analysis, had a post mortem diagnosis made 
based on a histological finding of histiocytic infiltration with haemophagocytosis in multiple 
organs. He was four months old at the time of his death. His older sister who was living in 
England, suffered from a neurodegenerative disease characterized by acute febrile episodes 
with thrombocytopenia. Although extensively investigated the cause of her condition had not 
been found but was presumed to be due to a hereditary metabolic disorder. After her brother’s 
death, the possibility of a haemophagocytic syndrome as an explanation for her symptoms was 
considered, and specimens of both siblings were re-examined. The sister died before a liver 
biopsy could be performed but retrospective comparison suggested that these patients may 
have suffered from a familial form of HLH. This diagnosis was made well before established 
diagnostic criteria were proposed or were in use.  
The earliest patient included in this analysis was diagnosed in 1991. He retrospectively fulfilled 
5 of the 8 criteria: documented fever, splenomegaly, cytopaenias, haemophagocytic 
histiocytosis on bone marrow and liver biopsy and raised serum triglycerides (at that time the 
upper limit of normal for serum triglycerides was 1.6 according to the laboratory reference 
range). The child was treated with steroids, cyclosporin and etoposide and responded to 
therapy.  
Formal diagnostic criteria were first proposed in 1994 and since that time fourteen patients 
have been diagnosed with HLH at Red Cross Hospital (ten of these in the last two years). This is 
a clear reflection of the increasing awareness amongst physicians of HLH as a distinct 
haematological entity.  
An HIV positive patient who had defaulted highly active antiretroviral therapy, developed HLH 
and had positive cultures for multiple infections. Frequent infections are part of the clinical 
course of both HIV infection and HLH and in this patient, deciding which organism was the 












Similarly other illnesses such as Kawasaki disease can cause diagnostic difficulties because of 
similarities in presentation. One patient with Kawasaki disease did not respond to initial 
treatment with IVIG. She developed bicytopaenia requiring multiple blood product transfusions 
and had a markedly raised LDH. Further investigations revealed hyperferritinaemia, raised 
triglycerides and hypoferritinaemia. A bone marrow showed features compatible with HLH25.  
CNS involvement is reported in 73-75% of patients with HLH16, 17. Our cohort did not display the 
high incidence reported in other series. Many patients were noted to be irritable, but this was 
usually attributed to fever and acute illness. This may imply that more subtle signs of CNS 
involvement may have been missed. Two patients were noted to have developmental 
regression, one prior to developing HLH and the other thereafter. This may reflect that the 
developmental history is typically not explored sufficiently when dealing with an acutely ill child 
or when referring patients with more pressing problems. 
The two most consistent laboratory findings amongst these patients were anaemia and 
hyperferritinaemia. However, the differential diagnosis for anaemia is substantially broader, 
making a markedly elevated serum ferritin a far more reliable indicator of a possible histiocytic 
disorder. 
It is our institutional policy to start dexamethasone monotherapy for non-EBV related HLH as 
most patients respond to steroids alone. Our institutional indications for etoposide and 
cyclosporine co-therapy are: 
 Proven EBV- related HLH 
 Refractory disease 
 Relapsed disease 
 Suspected primary HLH  
 Critically ill patients with multi-organ failure, or life threatening complications 
There are multiple reasons for this policy. One is the expense of cyclosporin, as well as the cost 












patients are referred from distant areas and where space and time constraints within the 
hospital pose very real challenges. 
Although the development of diagnostic criteria has greatly assisted paediatricians in diagnosis 
of HLH, there are limitations in developing countries. 
Firstly, there is a bias towards laboratory criteria. Resource constraints limit the usefulness of 
diagnostic criteria that are very laboratory dependant. Limited facilities also affect the time 
taken to obtain results, make a diagnosis and commence treatment. For example, soluble IL-2 
receptor levels and NK-activity tests are not available in South Africa. Patients therefore need 
to fulfill five of the remaining six criteria to make a diagnosis of HLH.  
In addition, the disease process is dynamic. Diagnostic criteria are always limited to capturing a 
patient at a specific moment in time. Although a patient may not meet the criteria at first 
presentation, he or she may do so at a later stage as the disease progresses. Serial 
examinations and investigations may be needed to make the diagnosis. This may not be 
practical in a setting where many patients are required to travel vast distances to referral 
hospitals. 
Diagnostic guidelines which rely more heavily on clinical criteria would assist doctors in 
resource constrained environments. This is the case for a newly proposed modification of the 
guidelines (see Table II) which, although using many of the same criteria, is also less stringent, 
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Addendum A: Diagnostic Criteria 
Table I.  Revised Diagnostic Guidelines for HLH                                                   
 The diagnosis HLH can be established if one of either1 or 2 below is fulfilled 
1. A molecular diagnosis consistent with HLH 
2. Five of the eight criteria below are met: 
A) Initial diagnostic criteria (to be evaluated in all patients with HLH) 
 Fever 
 Splenomegaly 
 Cytopaenia affecting 2 or more lineages 
- Hb < 9g/dL ( in neonates < 10g/dL) 
- Platelets  < 100x109/L 
- Neutrophils  < 1.0x109/L 
 Hypertriglyceridaemia – fasting triglycerides > 3  mmol/L   
        and/or  
        hypofibrinogenemia – fibrinogen < 1.5 g/L 
 Haemophagocytosis in bone marrow, spleen or lymph nodes, 
No evidence of malignancy 
 
B) New diagnostic criteria 
 Low or absent NK-cell activity (according to local laboratory reference) 
 Ferritin > 500 mcg/L 
 Soluble IL-2 receptor > 2400 U/mL 
Comments 
 If haemophagocytic activity is not proven at the time of presentation, further search for haemophagocytic activity is encouraged.  If the bone 
marrow specimen is not conclusive, material may be obtained from other organs. Serial marrow aspirates over time may also be helpful. 
 The following findings may provide strong supportive evidence for the diagnosis: a) spinal fluid pleocytosis (mononuclear cells) and/ or elevated 
spinal fluid protein, b) histiological picture in the liver resembling chronic persistent hepatitis (biopsy). 
 Other abnormal clinical and laboratory findings consistent with the diagnosis are: cerebromeningeal symptoms, lymph node enlargement, 
jaundice, oedema, skin rash. Hepatic enzyme abnormalities, hypoproteinemia, hyponatremia, VLDL increased, HDL decreased. 














Table II.  Proposed Diagnostic Criteria, 2009 
1. Molecular diagnosis of haemophagocytic lymphohistiocytosis (HLH) Or   
    X- linked lymphoproliferative syndromes (XLP) 
2. Or at least 3 of 4: 
 Fever  
 Splenomegaly  
 Cytopenias (minimum 2 cell lines reduced)  
 Hepatitis 
3. And at least 1 of 4:  
 Haemophagocytosis  
 Increased ferritin  
 Increased soluble IL-2 receptor 
 Absent or very decreased NKC function 
4. Other results supportive of HLH diagnosis 
 Hypertriglyceridaemia  
















Addendum B: Patient Cohort 










1 Male Mixed ancestry 27 Pneumococcal endocarditis ADF 
2 Male Black 15 AML DD 
3 Male Mixed ancestry 79 ALL DD 
4 Male Black 14 CMV, RSV AWD 
5 Male Black 10 NCC AWD 
6 Male Black 11 EBV DU 
7 Male Black 36 EBV ADF 
8 Female Mixed ancestry 20 NCC ADF 
9 Female Black 68 NCC DU 
10 Female Black 33 NCC Lost 
11 Female Black 147 T cell lymphoma ADF 
12 Female Bangladeshi 26 NCC ADF 
13 Female Mixed ancestry 73 Kawasaki Disease ADF 
14 Female Black 9 
Anaplastic large cell 
lymphoma 
AWD 
15 Female Black 225 SLE,EBV AWD 
 
NCC No clear cause, ADF Alive disease free, DD Died of disease, AWD Alive with disease,  
















Table IV. Patient Biochemical / Diagnostic Markers 
 
M male, F female, LDH Lactacte dehydrogenase, ESR Erythrocyte sedimentation rate, BM Bone marrow, CSF 
Cerebrospinal fluid, LB Liver biopsy, LN Lymph node biopsy, VL Viral load, WBC White Blood Count, Plts Platelets. 
Numbers highlighted indicate abnormal values relative to the diagnostic criteria. WBC seen is the total white 
blood count and not the total neutrophil count. EBV VL > 4 log considered significantly elevated. 
*Reference ranges variable dependant on age and gender. The range stated is for children from 9-225 months of 
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6-10.5* 140-340   
Diagnostic 
criteria 
>500 >3.0 <1.6   <9.0 <5 <100   
1 6502 4.6 1 608 5 4.5 18.8 31 BM 3.2 




3 1953 4.2 1.1 348 1 9 2.6 39 BM 4.8 
4 885 2.3 3.8 272 4 8.3 22.3 53 BM - 
5 9424 2.8 3 3497 62 9 9.9 141 BM, CSF 3.3 
6 811 1.5 0.1 590  3.2 35.1 16 BM 6.5 
7 1533 2.3 6.4 467 150 3.6 26.7 94 BM 3.7 
8 4047 6.1 0.3 1134 125 7.3 31.2 109 BM 3.7 
9 291 1.4 2.3 893 40 8.6 3.4 115 BM - 
10 - 1.9 - 120 - 4.3 4.9 22 BM, LB - 
11 4174 5.5 2.8 270 102 11.3 1 31 BM 4 
12 4338 8.4 2.1 935 35 10.4 15.7 101 BM 3.3 
13 10000 3.5 0.8 4873 19 8 27.2 91 BM 4 
14 4635 5.4 - 224 - 10 63.1 23 BM, LN - 
















Hepar Spleen Skin  Oedema LN CNS Cardiac Resp Haem Other 
1 unknown + +  +   +   + 
2 unknown + + +  + +  + +  
3 No fever    +  +  +   
4 No fever   +     +  + 
5 10 + + +  +   + + + 
6 19 + + + + +  + +  + 
7 1 + + +  +   +  + 
8 51 + +  + +      
9 16 + +  +      + 
10 unknown + +  +     +  
11 unknown      +     
12 21 + + +  +     + 
13 17   + +  + +    
14 unknown + + + + + +  +   
15 unknown +     +  +   
 
Hepar Hepatomegaly, Spleen Splenomegaly, Skin involvement included rash, subcutaneous nodules or any 
documented skin lesions, LN  Lymph nodes, CNS involvement included meningism, hydrocephalus, headache, 
hypertonia, twitching, abnormal gait, lethargy, hypotonia, dizziness, neuroregression, unexplained pain, strabismus, 
decreased  level of consciousness, Cardiac signs included murmur, cardiac failure, Resp respiratory symptoms including 
cough,airway obstruction and unspecified respiratory illness, Haem haematological involvement included bleeding, 
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Haemophagocytic Lymphohistiocytosis (HLH) is a rare disease in children1, and presents many 
diagnostic difficulties. Without prompt intervention, the disease typically runs a rapidly fatal 
course. Diagnostic criteria were proposed by the Histiocyte Society in 1991 and have since been 
modified. Included in these criteria is a ferritin level > 500mcg/L2. Although not diagnostic, a 
high ferritin level is highly suggestive of HLH. Serum ferritin assays are more accessible and cost 
effective compared to other biochemical markers, particularly in resource limited settings. 
Fifteen patients with HLH were treated at Red Cross War Memorial Children’s Hospital between 
1991 and 2010. Hyperferritinaemia was a consistently reliable finding (93%) compared to either 
serum fibrinogen or triglycerides which were elevated in only half of the patients. It is our 
contention that a complete blood count and serum ferritin (in addition to clinical criteria and 
tissue examination of marrow and / or CSF) is probably the single most cost effective and 
clinically helpful means to make the diagnosis of HLH where laboratory access is limited. 
 
 



























Haemophagocytic Lymphohistiocytosis (HLH) is a rare disease in children with an estimated 
incidence of 0.12 cases per 100 000 children1. As no published series is available, the incidence 
in Africa is unknown. Without treatment the disease runs an often fatal course, making prompt 
diagnosis a priority. The diagnosis may be difficult since HLH is a diagnosis of exclusion with no 
pathognomonic features, and a clinical picture which may be vague and varied. For this reason 
it is usually not considered early as a differential diagnosis to exclude and so treatment delays 
are inevitable.  
In order to aid diagnosis, a set of diagnostic criteria including clinical and biochemical markers 
was proposed by the Histiocyte Society in 19912. These were modified in 2004 (Table I), and 
new recommendations have been made since but have not yet been codified (Table II). 
Included in these criteria is a ferritin level > 500mcg/l2. In a study by Allen et al a ferritin level 
>10000mcg/l was found to be 90% sensitive and 96% specific for HLH (98% if fever added as a 
criterion) 3. In a series of patients including both viral- and malignancy associated HLH, Esumi et 
al found ferritin levels to be elevated at diagnosis, with further increases at the onset of DIC. 
Patients with sustained high ferritin levels after three months died, while those with decreased 
levels survived, suggesting that ferritin level may be a useful marker to monitor disease activity 
and not just as an indicator of the presence of disease4.   Serum ferritin levels are more readily 
available in most laboratories compared to functional NKC assays or IL-2 alpha receptor serum 
assays, which is of particular importance in Africa where laboratory services are often limited or 
unavailable.  
Ferritin production is up-regulated by pro-inflammatory cytokines from the NKC pathway3, the 
activated yet ineffective pathway in HLH. The differential diagnosis for conditions associated 
with hyperferritinaemia include other infections, auto-immune disease, like juvenile systemic 
arthritits5, and several very rare syndromes which include lysinuric protein intolerance (LPI), 
congenital haemochromatosis and hereditary hyperferritinaemia-cataract syndrome6. A high 














Materials and Methods 
Between March 1991 and September 2010 fifteen patients were diagnosed with HLH at Red 
Cross War Memorial Children’s Hospital. This diagnosis was made based on the HLH diagnostic 
criteria (Table I). These criteria were modified for our local use to include an abnormal CSF with 
other tissues like the bone marrow and lymph nodes. This was done because CSF changes may 
be present even without any clinical features5 or conversely CSF may appear normal, even in 
patients with symptomatic CNS involvement7. For this reason, Janka et al recommend a lumbar 
puncture be done in all patients5 as CNS involvement is associated with a worse outcome7. Also,  
NKC activity testing and IL2 levels are not available at our institution. Cases were identified 
using the institutional oncology registry, and a retrospective review of data was performed 
using hospital folders. 
Prior to 1991 four patients had histopathological features compatible with a haemophagocytic 
syndrome. These patients presented prior to there being specific diagnostic recommendations, 
as such many of the investigations required to meet the criteria were not performed, resulting 
in insufficient evidence for the diagnosis to be made. These patients, as well as those with 
Langerhans cell histiocytosis, malignant histiocytosis or those who did not meet the diagnostic 
criteria for HLH were excluded from this series.  
 
Results 
Eight of the 15 patients were female and seven male. The median age at diagnosis of 27 months 
(10-79 months) for males and 75 months (9-225 months) for females. Three patients were 
under 1 year of age at diagnosis, the age when primary HLH is more likely to present6. 
Ten patients are black, four of mixed ancestry and one patient is Bangladeshi. There are no 
Caucasians in our cohort. None of the patients included in the study had a documented family 
history of HLH, although none of the folders contained any specific history of consanguity or 
unexplained family illnesses or deaths related to haematological problems.  All of the patients 
included in the group were classified as having secondary HLH. Three patients had EBV infection 












Precipitants were varied and included CMV and RSV (1) and pneumococcal endocarditis (1), 
Kawasaki disease (1), SLE (1). Four patients had malignancy-associated HLH: ALL (1), AML (1), T-
cell lymphoma (1), and anaplastic large cell lymphoma (1).  
The median time to achieve a diagnosis once the children had arrived at our own institution 
was 13.7 days (1- 38 days). Discussion prior to referral undoubtedly shortened the interval to 
diagnosis in certain cases.  
Fever was documented in 13 (87%) patients. Splenomegaly was documented in 10(67%) 
patients. Despite hepatomegaly not being a diagnostic criterion, it was present in 11(73%) 
patients. Other common features were rash (7,[47%]), oedema (8,[54%]) and lymphadenopathy 
(7,[47%]). By comparison, Henter et al found the following clinical features of patients in a 
literature review, a population based study and the FHL Registry , respectively1 : fever (91%, 
100%, 93%), splenomegaly (98%, 100%, 97%), hepatomegaly (94%, 97%, no data available) rash 
(6%, 65%, 24%), lymphadenopathy (17%, 52%, 31%). Five patients were found to have clinical 
CNS involvement which is lower than the 75% found in a series by Hallahan et al, although in 
most of these patients CNS features were not present initially but developed later in the clinical 
course7. 
Of 14 patients who had documented serum ferritin levels, 13 met the diagnostic criterion of 
levels above 500mcg/L.  
All patients had multiple complete blood counts. The first values demonstrating an abnormality 
were recorded, and in many cases results continued to deteriorate before normalising. Twelve 
of 15 had serum haemoglobin levels of 9.0g/dL or less. Five patients had total white blood 
count values under 4x109/L and 10 had platelet counts of less than 100 x109/L (13 – 145x109/L). 
Seven of 14 patients who had serum triglyceride levels tested had elevations in excess of 
3mM/L. Six of 13 patients had fibrinogen levels below 1.5g/L.  
All patients had bone marrow biopsies at diagnosis. All bar one demonstrated 
haemophagocytosis with histiocytic infiltration on initial or follow up biopsy. One patient had 
haemophagocytosis present on a lymph node biopsy. Three of the four patients who had liver 
biopsies demonstrated haemophagocytosis (Table III). 
Thirteen patients were commenced on steroids. Ten were started on dexamethasone, two on 
prednisone. One of the patients started on prednisone initially was changed to dexamethasone 
nine days later. 












Whether or not patients received etoposide or not did not seem to have any bearing on  
outcome, keeping in mind that it is a small cohort of patients and that our criteria for etoposide 
were fairly strict (primary steroid non-responders, proven EBV associated HLH, refractory or 
reactivated HLH).  
No patients required bone marrow transplant.  
Four patients have died; one from refractory HLH, one from reactivated HLH, one from end 
stage HIV infection and one from an unknown cause. Ten patients are still alive; six are disease 
free and four are alive with disease: one with refractory disease on treatment, one with 
reactivated disease on second line treatment and two still on the induction phase of treatment. 
One patient has been lost to follow up. 
 
Discussion 
The diagnosis of HLH in resource constrained environments is made more difficult by the 
reliance on laboratory criteria which are often unavailable or limited. New proposed 
modifications to the diagnostic criteria (Table II) will help to make this less so, as they are 
somewhat less laboratory focused compared to the current criteria (Table I). However, the onus 
is still on the clinician to actively make the diagnosis, and to pursue treatment early on.  
The costs related to specific investigations are often not considered by the user. Cost 
considerations often move local, national or institutional groups to relook at diagnostic and 
treatment criteria, in order to balance what is best for the patient against what is affordable for 
a service provider. South Africa, although arguably more fortunate than most  African countries, 
is not exempt to these pressures and we have had to make institutional alterations to the 
treatment guidelines for patients with HLH because of  the costs of tests (cyclopsorin levels) 
and drugs (cyclosporin, in particular). Furthermore these “hard” costs do not take include 
hidden expenses of difficulty with access, transport and accommodation for poor patients, 
especially those required to attend outpatient clinics several times a week. Table IV has a list of 
the cost of the laboratory tests typically involved in the diagnosis and followed up in HLH. 
Because the disease is a dynamic process, investigations may need to be repeated before 












some hospitals and some tests not available at all (for example, soluble IL-2 receptor levels and 
NKC activity). 
This then raises the question as to what the most cost effective and clinically instructive 
strategy is. In our series, hyperferritinaemia was a consistently reliable finding (93%) compared 
to either serum fibrinogen or triglycerides which were elevated in only half of the patients. This 
finding is supported by others studies in which a ferritin level >500 mcg/l was found in 100% of 
patients with HLH3.  
Taking clinical comparators into account, fever was found in 87% of patients, hepatomegaly 
(73%) and anaemia (67%) were common findings but the differential diagnosis for each of 
these, or even in combination, remains much wider than for those with significant 
hyperferritinaemia, particularly in our region with high rates of endemic tuberculosis and HIV 
infection.  
It is our contention that a complete blood count and serum ferritin (in addition to clinical 
criteria and tissue examination of marrow with or without a CSF ) is probably the single most 
cost effective and clinically helpful means to make the diagnosis and that serum fibrinogen    
and /or triglycerides are useful adjuncts, when there is still sufficient doubt about the diagnosis. 
A full set of investigations (complete blood count, fibrinogen, ALT, LDH, triglycerides, ferritin, 
bone marrow aspiration) will cost roughly $130 US per patient. Based on our small group of 
patients it seems reasonable to limit investigations to a complete blood count, serum ferritin 
and bone marrow biopsy examination (at a cost of approximately $95 US), and initially forego 
the others, considering that the ferritin is consistently more reliable as an indicator of disease, 
compared to serum triglycerides and fibrinogen; a cost saving of approximately $35 US per 
patient.  
Rationalizing costs should be a priority in any clinical care setting, and often measures taken to 
limit costs that arise out of necessity, subsequently have real implications for how patients are 
managed in environments even where resources are not limited.  
There are a number of weaknesses of our review. The small size of the cohort limits it’s power 
and thus the interpretation of the findings. Although we believe some of the excluded patients 
did have HLH, they did not meet our inclusion criteria. Our inability to do certain tests due to 












also had an impact on what upfront treatment could be offered. Some patients responded 
adequately to steroids alone, which may imply an immunological phenotype which is different 
to those who do not. We are unable to pre-empt which patients as these more sophisticated 
tests are not available at our institution. Survival analysis was not possible since some of the 
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Table I.  Revised Diagnostic Guidelines for HLH 
 The diagnosis HLH can be established if one of either1 or 2 below is fulfilled 
1. A molecular diagnosis consistent with HLH
2. Five of the eight criteria below are met:
A) Initial diagnostic criteria (to be evaluated in all patients with HLH)
Fever
Splenomegaly
Cytopaenia affecting 2 or more lineages
o Hb < 9g/dL ( in neonates < 10g/dL)
o Platelets  < 100x109/L
o Neutrophils  < 1.0x109/L
Hypertriglyceridaemia – fasting triglycerides > 3 mmol/L 
      and/or  
 hypofibrinogenemia – fibrinogen < 1.5 g/L 
Haemophagocytosis in bone marrow, spleen or lymph nodes,
No evidence of malignancy
B) New diagnostic criteria
Low or absent NK-cell activity (according to local laboratory reference)
Ferritin > 500 mcg/L
Soluble IL-2 receptor > 2400 U/mL
Comments
If haemophagocytic activity is not proven at the time of presentation, further search for haemophagocytic activity is encouraged. If the bone
marrow specimen is not conclusive, material may be obtained from other organs. Serial marrow aspirates over time may also be helpful.
The following findings may provide strong supportive evidence for the diagnosis: a) spinal fluid pleocytosis (mononuclear cells) and/ or elevated
spinal fluid protein, b) histiological picture in the liver resembling chronic persistent hepatitis (biopsy).
Other abnormal clinical and laboratory findings consistent with the diagnosis are: cerebromeningeal symptoms, lymph node enlargement,
jaundice, oedema, skin rash. Hepatic enzyme abnormalities, hypoproteinemia, hyponatremia, VLDL increased, HDL decreased.













Table II. Proposed Modifications to Diagnostic Criteria, 2009 
1. Molecular diagnosis of haemophagocyte lymphohistiocytosis (HLH)  
      Or X- linked lymphoproliferative syndromes (XLP) 
2. Or at least 3 of 4: 
 Fever  
 Splenomegally  
 Cytopenias (minimum 2 cell lines reduced)  
 Hepatitis 
3. And at least 1 of 4:  
 Haemophagocytosis  
 Increased Ferritin  
 Increased soluble IL-2 receptor 
            Absent or very decreased NKC function 
4. Other results supportive of HLH diagnosis 
 Hypertriglyceridaemia  





























ADF alive disease free, DD died of disease, AWD alive with disease, DU death unrelated, CSF cerebrospinal fluid, VL 
viral load, TG triglycerides, Fib Fibrinogen. D Dexamethasone, P Prednisone, E Etoposide, C Cyclosporin  
 
Numbers highlighted indicate abnormal values relative to the diagnostic criteria. WBC seen is the total white blood 































Histiocyte infiltration & 
Haemophagocytosis 
 








  >500 >3.0 <1.6 <9.0  <100    
1 27 ADF 6502 4.6 1 4.5 18.8 31 bone marrow 3.2 D 
2 15 DD 4193 - 0.6 2.9 2.2 13 
bone marrow, 
CSF, liver biopsy 
- P,E 
3 79 DD 1953 4.2 1.1 9 2.6 39 bone marrow 4.8 D, E 
4 14 AWD 885 2.3 3.8 8.3 22.3 53 bone marrow - D, E 
5 10 AWD 9424 2.8 3 9 9.9 141 bone marrow, CSF 3.3 D 
6 11 DU 811 1.5 0.1 3.2 35.1 16 bone marrow 6.5 - 
7 36 ADF 1533 2.3 6.4 3.6 26.7 94 bone marrow 3.7 D 
8 20 ADF 4047 6.1 0.3 7.3 31.2 109 bone marrow 3.7 D, P 
9 68 DU 291 1.4 2.3 8.6 3.4 115 bone marrow - - 




11 147 ADF 4174 5.5 2.8 11.3 1 31 bone marrow 4 D 
12 26 ADF 4338 8.4 2.1 10.4 15.7 101 bone marrow 3.3 D 
13 73 ADF 10000 3.5 0.8 8 27.2 91 bone marrow 4 D 
14 9 AWD 4635 5.4 - 10 63.1 23 
bone marrow, 
lymph node biopsy 
- D,C,E 












Table IV. Costs of Laboratory Tests 
National Health Laboratory Services, South Africa 
Test Cost in SA Rands  Cost in US Dollars 
Complete Blood Count 107.00 15.98 
Fibrinogen 36.70 5.45 
ALT 55.10 8.20 
LDH 55.10 8.20 
Triglyceride 80.80 12.02 
Ferritin 126.70 18.85 
Bone marrow examination 395.82 58.77 
TOTAL (All tests) R857.22 $127.47 
TOTAL (CBC+ Ferritin+BM) R629.52 $93.60 
TOTAL saving R227.70 $33.87 
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